Bristol-Myers, AstraZeneca Team Up On $7B Amylin Deal
The companies said that Bristol-Myers will acquire all the outstanding shares of Amylin for roughly $31 per share in cash, an aggregate purchase price of about $5.3 billion. The Princeton, N.J.-based drugmaker will also assume Amylin's net debt and a contractual payment to Eli Lily & Co., a combined commitment of $1.7 billion.
Already a subscriber? Click here to login